Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 401–500 of 1,056
van de Vijver, M., van de Bersselaar, R., Devilee, P., Cornelisse, C., Peterse, J., & Nusse, R. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.5.2019 · Cited by 330
“reported on the correlation between amplification of the neu gene and relapse and survival in breast cancer (31).”
BackgroundHigh Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment
Carter, P., Kelley, R. F., Rodrigues, M. L., Snedecor, B., Covarrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M., Kotts, C. E., Carver, M. E., et al. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-163 · Cited by 330
Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer
Bishayee, A. (2011) · Frontiers in Bioscience · doi:10.2741/3730 · Cited by 330
“These findings suggest that CDDO could be beneficial for therapy of patients with HER2overexpressing breast cancer, an aggressive form of disease characterized by significantly reduced survival times (105).”
BackgroundSeol, H., Lee, H. J., Choi, Y., Lee, H. E., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., & Park, S. Y. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.36 · Cited by 330
Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C. R., HARRIS, R. A., Pagé, M., Smith, K. J., Guntrip, S. B., Carter, M. C., Shaw, R. J., et al. (2001) · PubMed · Cited by 330
Gullick, W., Love, S., Wright, C., Barnes, D., Gusterson, B., Harris, A., & Altman, D. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.100 · Cited by 327
Molecular and Cellular Heterogeneity in Breast Cancer
Rivenbark, A. G., O’Connor, S. M., & Coleman, W. B. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.08.002 · Cited by 327
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Duffy, M. J., Reilly, D. M., O'Sullivan, C., O’Higgins, N. J., FENNELLY, J. J., & Andreasen, P. A. (1990) · PubMed · Cited by 327
Reduction to Homozygosity of Genes on Chromosome 11 in Human Breast Neoplasia
Ali, I. U., Lidereau, R., Theillet, C., & Callahan, R. (1987) · Science · doi:10.1126/science.3659909 · Cited by 324
O'Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M. J., Crown, J., O'Donovan, N., & Slamon, D. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1171 · Cited by 324
Self-citationWidschwendter, M., Siegmund, K. D., Müller, H. M., Fiegl, H., Marth, C., Müller-Holzner, E., Jones, P. A., & Laird, P. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3852 · Cited by 324
“We did not detect significant clustering of cases by HER2 status (22), menopausal status, relapse, death, grade, nodes, stage, or tumor diameter (data not shown).”
BackgroundImmune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation
Guillaume, T., Rubinstein, D. B., & Symann, M. (1998) · Blood · doi:10.1182/blood.v92.5.1471 · Cited by 323
Biscardi, J. S., Ishizawar, R. C., Silva, C. M., & Parsons, S. J. (2000) · Breast Cancer Research · doi:10.1186/bcr55 · Cited by 323
Gabos, Z., Sinha, R., Hanson, J., Chauhan, N., Hugh, J., Mackey, J. R., & Abdulkarim, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0250 · Cited by 321
Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.
Abbruzzese, J. L., Abbruzzese, M. C., Lenzi, R., Hess, K. R., & Raber, M. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.2094 · Cited by 320
Konecny, G. E., Meng, Y. G., Untch, M., Wang, H.-J., Bauerfeind, I., Epstein, M., Stieber, P., Vernes, J.-M., Gutierrez, J., Hong, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0951-3 · Cited by 318
Self-citationNasopharyngeal carcinoma—Review of the molecular mechanisms of tumorigenesis
Chou, J., Lin, Y., Kim, J., You, L., Xu, Z., He, B., & Jablons, D. M. (2008) · Head & Neck · doi:10.1002/hed.20833 · Cited by 317
Precision medicine for metastatic breast cancer—limitations and solutions
Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.123 · Cited by 317
LOSS OF CONSTITUTIONAL HETEROZYGOSITY IN HUMAN CANCER
Lasko, D., Cavenee, W., & Nordenskjöld, M. (1991) · Annual Review of Genetics · doi:10.1146/annurev.ge.25.120191.001433 · Cited by 316
LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer
Shi, S.-J., Wang, L.-J., Yu, B., Li, Y.-H., Jin, Y., & Bai, X.-Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3457 · Cited by 316
“Erb2/HER2 is amplified and overexpressed in 25%–30% of human breast cancers [3].”
Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.
Bargmann, C. I., & Weinberg, R. A. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03044.x · Cited by 315
Heneghan, H. M., Miller, N., Kelly, R., Newell, J., & Kerin, M. J. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0103 · Cited by 315
Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis
Putti, T. C., El‐Rehim, D. M. A., Rakha, E. A., Paish, C. E., Lee, A. H. S., Pinder, S. E., & Ellis, I. O. (2004) · Modern Pathology · doi:10.1038/modpathol.3800255 · Cited by 313
“36 In the present study, CerbB2 positivity was seen in almost 45% of ER-negative cases, although the overall expression is around 30% in the entire ER-positive and -negative series and in series reported by others”
Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.008 · Cited by 312
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Bange, J., Prechtl, D., Cheburkin, Y. V., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Müller, S., Gärtner, S., Sures, I., et al. (2002) · PubMed · Cited by 312
Self-citationElevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
Leitzel, K., Teramoto, Y. A., Konrad, K., Chinchilli, V. M., Volas, G. H., Grossberg, H., Harvey, H., Demers, L., & Lipton, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1129 · Cited by 312
The life and death of gene families
Demuth, J. P., & Hahn, M. W. (2009) · BioEssays · doi:10.1002/bies.080085 · Cited by 311
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., & Song, E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216887 · Cited by 311
Press, M. F., Sauter, G., Bernstein, L., Villalobos, I. E., Mirlacher, M., Zhou, J.-Y., Wardeh, R., Li, Y.-T., Guzman, R., Ma, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0636 · Cited by 311
“In this report, we used FISH assay results as our gold standard for purposes of assessing sensitivity, specificity, and overall agreement because HER-2 status as determined by FISH analysis is similar to the known ‘‘true’’ molecular status as determined by a comprehensive molecular analysis in frozen tissue (3, 20, 21…”
BackgroundMethodSelf-citationPerik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T. A., de Korte, M. A., Jonkman, S., Kosterink, J. G. W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8448 · Cited by 310
HER2 testing in gastric cancer: An update
Abrahao-Machado, L. F., & Scapulatempo-Neto, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i19.4619 · Cited by 310
Kokai, Y., Myers, J. N., Wada, T., Brown, V. I., LeVea, C. M., Davis, J. G., Dobashi, K., & Greene, M. I. (1989) · Cell · doi:10.1016/0092-8674(89)90843-x · Cited by 309
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M., Verhest, A., Bernard-Marty, C., Piccart, M. J., & Larsimont, D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf252 · Cited by 309
“The Her-2 oncoprotein (for a review see [5, 6]) is a transmembrane receptor, belonging to the epidermal growth factor receptor (EGFR) family, with tyrosine kinase activity that has been associated with shortened survival [7], enhanced aggressiveness [7, 8] and other poor prognostic factors.”
BackgroundMarino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309
MacDiarmid, J. A., Mugridge, N. B., Weiss, J. C., Phillips, L., Burn, A. L., Paulin, R. P., Haasdyk, J. E., Dickson, K.-A., Brahmbhatt, V. N., Pattison, S. T., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.012 · Cited by 307
“…arm recognizes the O-antigen component of the mini- cell surface LPS and the other, a cell-surface receptor specific for the mammalian cell to be targeted, for exam- ple, EGFR (El-Rayes and LoRusso, 2004) or HER2/neu re- ceptor (Slamon et al., 1987) on breast and ovarian cancer cells, respectively.”
BackgroundMethodCardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Bird, B. R. J. H., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 307
Lv, P., Li, H., Sun, J., Zhou, Y., & Zhu, H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.034 · Cited by 307
Leary, R. J., Lin, J. C., Cummins, J., Boca, S., Wood, L. D., Parsons, D. W., Jones, S., Sjöblom, T., Park, B.-H., Parsons, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808041105 · Cited by 306
“Our analyses identified several converging gene pathways, including the ERBB2, EGFR, and PI3K pathways, that were affected by copy number changes and point alterations in both breast and colorectal cancers.”
BackgroundInfluentialTrastuzumab in the Treatment of Breast Cancer
Hortobagyi, G. N. (2005) · New England Journal of Medicine · doi:10.1056/nejme058196 · Cited by 306
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Mano, M. S., Neciosup, S. P., Tseng, L.-M., Zhang, Q., Shen, K., Liu, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00051-0 · Cited by 306
Self-citationPrognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer.
Rudland, P. S., Platt-Higgins, A. M., Renshaw, C., West, C. R., Winstanley, J. H., Robertson, L. B., & Barraclough, R. (2000) · PubMed · Cited by 305
Taking the Study of Cancer Cell Survival to a New Dimension
Jacks, T., & Weinberg, R. A. (2002) · Cell · doi:10.1016/s0092-8674(02)01229-1 · Cited by 304
Role of HER2 gene overexpression in breast carcinoma
M�nard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200002)182:2<150::aid-jcp3>3.0.co;2-e · Cited by 303
Genetic alterations in breast cancer
Bièche, I., & Lidereau, R. (1995) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870140402 · Cited by 303
Targeted Therapy in Breast Cancer
Ross, J. S., Fletcher, J. A., Bloom, K. J., Linette, G. P., Stec, J., Symmans, W. F., Pusztai, L., & Hortobagyi, G. N. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400001-mcp200 · Cited by 303
Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.1974 · Cited by 302
Christianson, T. A., Doherty, J. K., Lin, Y.-J., Ramsey, E. E., Holmes, R. S., Keenan, E. J., & Clinton, G. M. (1998) · PubMed · Cited by 302
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Ahn, S., Woo, J. W., Lee, K., & Park, S. Y. (2019) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2019.11.03 · Cited by 302
“In breast cancers, HER2 gene is amplified in 15%–20% of invasive breast cancers and its amplification is closely linked to HER2 protein overexpression [1,2].”
BackgroundChia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., & Gelmon, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8659 · Cited by 301
“HER2 is amplified in approximately 10% to 20% of breast cancers.(7,8) Preclinical studies have demonstrated that amplification of HER2 or overexpression of its protein product play an important role in human breast cancer biology.”
BackgroundZhu, Y., Chandra, P., & Shim, Y.-B. (2013) · Analytical Chemistry · doi:10.1021/ac302923k · Cited by 301
Translating insights from the cancer genome into clinical practice
Chin, L., & Gray, J. W. (2008) · Nature · doi:10.1038/nature06914 · Cited by 300
“Shortly after these findings, ERBB2 amplification was found in ∼30p of primary breast-cancer tumours, and this amplification was associated with a short survival time and short time to relaps”
BackgroundP27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells
Nahta, R., Takahashi, T., Ueno, N. T., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3900 · Cited by 298
“The her-2 (erbB2/neu) gene is amplified and/or overexpressed in approximately 20–30% of invasive breast carcinomas and is associated with increased metastatic potential and decreased overall survival (1).”
BackgroundLane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
“Furthermore, overexpression of ErbB2 correlates with a poor patient prognosis not only in breast cancer (24, 59, 70, 71) but also in other malignancies, such as ovarian (71) and gastric (84) cancers.”
BackgroundGenetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review
Montesano, R., Holestein, M., & Hainaui, P. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960621)69:3<225::aid-ijc13>3.0.co;2-6 · Cited by 297
Dawson, J. P., Berger, M. B., Lin, C.-C., Schlessinger, J., Lemmon, M. A., & Ferguson, K. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7734-7742.2005 · Cited by 297
Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H., LEES, A. W., Jamil, N. S. M., Hanson, J., Jenkins, H., Krause, B. E., & McBlain, W. A. (1991) · PubMed · Cited by 296
Aparicio, A. M., Shen, L., Tapia, E. L. N., Lu, J.-F., Chen, H.-C., Zhang, J., Wu, G., Wang, X., Troncoso, P., Corn, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1259 · Cited by 295
Robertson, S., Azizpour, H., Smith, K., & Hartman, J. (2018) · Translational Research · doi:10.1016/j.trsl.2017.10.010 · Cited by 295
“HER2 protein overexpression by HER2 gene amplification is seen in approximately 15% of early breast tumors and associated with poor prognosis.(38,39) But HER2 is also a target for anti-HER2 therapy that dramatically improves the outcome for this group of patients.”
BackgroundMonoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 294
“When radioactive probes derived from the cDNA sequence encoding p185 hER2 were used to screen DNA samples derived from breast cancer patients, amplification of the HER2 protooncogene was observed in about 30% of patient samples ( 9 ).”
Self-citationAndersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., Karlsson, P., Tange, U. B., Sørensen, P. G., Møller, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8213 · Cited by 294
Leyland-Jones, B., Gelmon, K., Ayoub, J.-P., Arnold, A., Verma, S., Dias, R., & Ghahramani, P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.109 · Cited by 293
Oncogenes, Growth Factors, and Signal Transduction
Flier, J. S., Underhill, L. H., Druker, B. J., Mamon, H. J., & Roberts, T. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212007 · Cited by 292
Nanopreparations for organelle-specific delivery in cancer
Biswas, S., & Torchilin, V. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.004 · Cited by 292
“Human epidermal receptor-2 (HER-2) is over-expressed in a majority of patients with breast cancer [37–39].”
BackgroundTamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer
Jordan, V. C. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706399 · Cited by 292
“Overexpression (gene amplification) of the human epidermal growth factor-2 (HER2) oncogene in human breast cancer is associated with a type of disease with a poor prognosis, that is independent of OER status (Slamon et al., 1987).”
BackgroundAttenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells.
Xu, L., Owens, L. V., Sturge, G. C., Yang, X., Liu, E. T., Craven, R. J., & Cance, W. G. (1996) · PubMed · Cited by 292
Yamauchi, H., Stearns, V., & Hayes, D. F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2334 · Cited by 291
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Schlam, I., & Swain, S. M. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00265-1 · Cited by 290
Molecular targets for breast cancer therapy and prevention
Bange, J., Zwick, E., & Ullrich, A. (2001) · Nature Medicine · doi:10.1038/87872 · Cited by 288
Self-citationPrat, M., Narsimhan, R. P., Crepaldi, T., Rita Nicotra, M., Natali, P. G., & Comoglio, P. M. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490302 · Cited by 287
Phosphate Recognition in Structural Biology
Hirsch, A. K. H., Fischer, F. R., & Diederich, F. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200603420 · Cited by 287
Thorpe, S. M., Rochefort, H., Garcia, M., Freiss, G., Christensen, I. J., Khalaf, S., Paolucci, F., Pau, B., Rasmussen, B. B., & Rose, C. (1989) · PubMed · Cited by 287
PTEN, PIK3CA, p-AKT, and p-p70S6K Status
Esteva, F. J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J. S., Sahin, A. A., Hortobagyi, G. N., & Yu, D. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090885 · Cited by 285
Adam, L., Vadlamudi, R., Kondapaka, S. B., Chernoff, J., Mendelsohn, J., & Kumar, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.28238 · Cited by 284
Yu, D., Wolf, J. K., Scanlon, M., Price, J. E., & Hung, M. (1993) · PubMed · Cited by 284
Zidan, J., Dashkovsky, I., Stayerman, C., Basher, W., Cozacov, C., & Hadary, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602738 · Cited by 282
“…growth factor receptor family, with tyrosine kinase activity, resulting in intracellular signalling and activation of genes involved in cell growth, which is associated with shortened survival, enhanced aggressiveness and other poor prognostic factors (Slamon et al, 1987; Tsuda et al, 1989).”
BackgroundNovosyadlyy, R., Lann, D. E., Vijayakumar, A., Rowzee, A., Lazzarino, D. A., Fierz, Y., Carboni, J. M., Gottardis, M. M., Pennisi, P. A., Molinolo, A. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2141 · Cited by 282
“Neu is a rodent analogue of the human ERBB2 gene, which is amplified and overexpressed in 30% of human breast carcinomas (23).”
Gene amplification in cultured cells.
Schimke, R. T. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68734-4 · Cited by 281
Hanna, W. M., Rüschoff, J., Bilous, M., Coudry, R. A., Dowsett, M., Osamura, R. Y., Penault-Llorca, F., van de Vijver, M., & Viale, G. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.103 · Cited by 281
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
Triple-negative/basal-like breast cancer: review
Rakha, E. A., & Ellis, I. O. (2009) · Pathology · doi:10.1080/00313020802563510 · Cited by 281
“amplification of HER2 in breast cancer was recognised in 1987.(9) HER2 is amplified in approximately 18–20% of breast cancers, and is more frequently observed in HR negative tumours.”
BackgroundThe Treatment of Breast Cancer
(1974) · Springer eBooks · doi:10.1007/978-94-011-7152-6 · Cited by 280
Transgenic Models of Tumor Development
Adams, J. M., & Cory, S. (1991) · Science · doi:10.1126/science.1957168 · Cited by 280
Wang, Y.-C., Morrison, G., Gillihan, R., Guo, J., Ward, R. M., Fu, X., Botero, M. F., Healy, N. A., Hilsenbeck, S. G., Phillips, G. L., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3067 · Cited by 280
“Approximately 20% of human breast cancers are HER2-amplified, and overexpression correlates with aggressive tumor behavior and poor patient outcome [4].”
BackgroundSafety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Tripathy, D., Slamon, D. J., Cobleigh, M., Arnold, A., Saleh, M., Mortimer, J. E., Murphy, M., & Stewart, S. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.557 · Cited by 280
“HER2 is overexpressed in approximately 20% to 25% of breast cancers [1-3].”
BackgroundSelf-citationClinical Cardiac Tolerability of Trastuzumab
Perez, E. A., & Rodeheffer, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.120 · Cited by 280
“[1,2].”
Neu and its ligands: From an oncogene to neural factors
Peles, E., & Yarden, Y. (1993) · BioEssays · doi:10.1002/bies.950151207 · Cited by 279
Greulich, H., Kaplan, B., Mertins, P., Chen, T.-H., Tanaka, K. E., Yun, C.-H., Zhang, X., Lee, S.-H., Cho, J., Ambrogio, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203201109 · Cited by 279
Membrane proteins and membrane proteomics
Tan, S., Tan, H. T., & Chung, M. C. M. (2008) · PROTEOMICS · doi:10.1002/pmic.200800597 · Cited by 279
“HER2 protein overproduction owing to gene amplification is found in 25–30% of breast cancers and confers a particularly aggressive biology [25].”
Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer
Gagliato, D. D. M., Gonzalez-Angulo, A. M., Lei, X., Theriault, R. L., Giordano, S. H., Valero, V., Hortobagyi, G. N., & Chavez-MacGregor, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7693 · Cited by 279
“The HER2 overexpression or amplification in primary tumors is associated with worse prognosis in untreated patients and might also correlate with other factors associated with poor prognosis, such as tumor grade and nodal status.(25-27) Trastuzumab-based chemotherapy is recognized as a key component of the adjuvant tr…”
BackgroundHER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
Jørgensen, J. T., & Hersom, M. (2012) · Journal of Cancer · doi:10.7150/jca.4090 · Cited by 279
“demonstrated that amplification of the HER2 gene in patients with breast cancer negatively impacted the recurrence of the disease and the survival [4].”
BackgroundResultRio, M. C., Bellocq, J. P., Gairard, B., Rasmussen, U. B., Krust, A., Koehl, C., Calderoli, H., Schiff, V, Renaud, R., & Chambon, P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9243 · Cited by 278
Luen, S. J., Salgado, R., Fox, S., Savas, P., Eng-Wong, J., Clark, E., Kiermaier, A., Swain, S. M., Baselga, J., Michiels, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30631-3 · Cited by 278
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Direct Interaction of a Ligand for the erb B2 Oncogene Product with the EGF Receptor and p185 erb B2
Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D., & Lippman, M. E. (1990) · Science · doi:10.1126/science.2218496 · Cited by 277
Self-citationPast, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
“HER2-Positive Disease In the late 1980s, HER2 gene amplification was recognized as a prognostic marker for poor clinical outcome in early-stage breast cancer.(67,68) While retrospective studies suggested a preferential benefit with adjuvant anthracycline regimens,(69) the true revolution in therapy for HER2-positive p…”
BackgroundCodony‐Servat, J., Albanell, J., López-Talavera, J. C., Arribas, J., & Baselga, J. M. (1999) · PubMed · Cited by 277
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer
Bruntz, R. C., Lindsley, C. W., & Brown, H. A. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009217 · Cited by 276
“As such, mutated or overexpressed growth factors such as the PDGF receptor and the EGFR are commonly observed in malignancies such as glioblastoma and breast cancer, respectively (Slamon et al., 1987; Shih and Holland, 2006).”
BackgroundDonehower, L. A., Godley, L. A., Aldaz, C. M., Pyle, R., Shi, Y. P., Pinkel, D., Gray, J., Bradley, A., Medina, D., & Varmus, H. E. (1995) · Genes & Development · doi:10.1101/gad.9.7.882 · Cited by 276
Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
Eaton, J. S., Miller, P. E., Mannis, M. J., & Murphy, C. J. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2015.0064 · Cited by 276
“HER2 is abundantly expressed in 10%–30% of primary human breast tumors(20,21); and tumor cells overexpressing HER2 often demonstrate aggressive growth associated with poorer clinical outcomes.(20,22) Despite these prognostic implications, HER2 is an attractive therapeutic target.”
Background
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.